These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 35746761)

  • 1. The In Vitro Replication, Spread, and Oncolytic Potential of Finnish Circulating Strains of Herpes Simplex Virus Type 1.
    Kalke K; Orpana J; Lasanen T; Esparta O; Lund LM; Frejborg F; Vuorinen T; Paavilainen H; Hukkanen V
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of γ34.5 in Glioblastoma Stem-Like Cells.
    Peters C; Paget M; Tshilenge KT; Saha D; Antoszczyk S; Baars A; Frost T; Martuza RL; Wakimoto H; Rabkin SD
    J Virol; 2018 Aug; 92(15):. PubMed ID: 29793956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Replication and Spread of Oncolytic Herpes Simplex Virus in Solid Tumors.
    Hong B; Sahu U; Mullarkey MP; Kaur B
    Viruses; 2022 Jan; 14(1):. PubMed ID: 35062322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy.
    Menotti L; Avitabile E
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Herpes Simplex Virus 1 Strains Circulating in Finland Demonstrates the Uncoupling of Whole-Genome Relatedness and Phenotypic Outcomes of Viral Infection.
    Bowen CD; Paavilainen H; Renner DW; Palomäki J; Lehtinen J; Vuorinen T; Norberg P; Hukkanen V; Szpara ML
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30760568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of non-replicative and oncolytic replication-selective HSV vectors.
    Epstein AL; Rabkin SD
    Trends Mol Med; 2024 Aug; 30(8):781-794. PubMed ID: 38886138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV.
    Jahan N; Ghouse SM; Martuza RL; Rabkin SD
    Viruses; 2021 Aug; 13(9):. PubMed ID: 34578321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of Oncolytic Herpes Simplex Virus with Therapeutic Genes of Interest.
    Kahramanian A; Kuroda T; Wakimoto H
    Methods Mol Biol; 2019; 1937():177-188. PubMed ID: 30706396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells.
    Petrovic B; Leoni V; Gatta V; Zaghini A; Vannini A; Campadelli-Fiume G
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29263257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic herpes simplex virus and immunotherapy.
    Ma W; He H; Wang H
    BMC Immunol; 2018 Dec; 19(1):40. PubMed ID: 30563466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors.
    Maldonado AR; Klanke C; Jegga AG; Aronow BJ; Mahller YY; Cripe TP; Crombleholme TM
    J Gene Med; 2010 Jul; 12(7):613-23. PubMed ID: 20603890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour-specific triple-regulated oncolytic herpes virus to target glioma.
    Delwar ZM; Liu G; Kuo Y; Lee C; Bu L; Rennie PS; Jia WW
    Oncotarget; 2016 May; 7(19):28658-69. PubMed ID: 27070093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy.
    Li H; Nakashima H; Decklever TD; Nace RA; Russell SJ
    Cancer Gene Ther; 2013 Aug; 20(8):478-85. PubMed ID: 23868101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved antitumor effectiveness of oncolytic HSV-1 viruses engineered with IL-15/IL-15Rα complex combined with oncolytic HSV-1-aPD1 targets colon cancer.
    Hu Z; Li Y; Yang J; Liu J; Zhou H; Sun C; Tian C; Zhu C; Shao M; Wang S; Wei L; Liu M; Li S; Wang J; Xu H; Zhu W; Li X; Li J
    Sci Rep; 2024 Oct; 14(1):23671. PubMed ID: 39389985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human Monocytes Are Suitable Carriers for the Delivery of Oncolytic Herpes Simplex Virus Type 1 In Vitro and in a Chicken Embryo Chorioallantoic Membrane Model of Cancer.
    Reale A; Krutzke L; Cadamuro M; Vitiello A; von Einem J; Kochanek S; Palù G; Parolin C; Calistri A
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers.
    Kang KD; Bernstock JD; Totsch SK; Gary SE; Rocco A; Nan L; Li R; Etminan T; Han X; Beierle EA; Eisemann T; Wechsler-Reya RJ; Bae S; Whitley R; Gillespie GY; Markert JM; Friedman GK
    Clin Cancer Res; 2022 Dec; 28(24):5419-5430. PubMed ID: 36239623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
    Todo T
    Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient Strategy for Synthesizing Vector-Free and Oncolytic Herpes Simplex Type 1 Viruses.
    Xiao H; Hu H; Guo Y; Li J; Zeng WB; Luo MH; Wang M; Hu Z
    ACS Synth Biol; 2024 Oct; 13(10):3268-3280. PubMed ID: 39358309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy.
    Ghonime MG; Cassady KA
    Cancer Immunol Res; 2018 Dec; 6(12):1499-1510. PubMed ID: 30352799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic HSV-1 suppresses cell invasion through downregulating Sp1 in experimental glioblastoma.
    Zhang J; Wang J; Li M; Su X; Tian Y; Wang P; Zhou X; Jin G; Liu F
    Cell Signal; 2023 Mar; 103():110581. PubMed ID: 36572188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.